FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:786-799 February 19, 2004 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Overactive bladder is a symptom complex that includes urinary urgency with or without urge incontinence, urinary frequency (voiding eight or more times in a 24-hour period), and nocturia (awakening two or more times at night to void).^1,2,3 The International Continence Society classifies overactive bladder as a syndrome for which no precise cause has been identified, with local abnormalities ruled out by diagnostic evaluation.^4,5 This review extends beyond the International Continence Society's current definition of overactive bladder, since a broader approach to this syndrome is essential for optimal management.^6,7

Because overactive bladder is a recently defined syndrome, its prevalence and natural . . . [Full Text of this Article]

Pathophysiology

Diagnostic Evaluation

Therapy

Nonpharmacologic Interventions

Drug Therapy

Summary

Source Information

From the Division of Geriatric Medicine and Gerontology, Wesley Woods Center, Center for Health in Aging, Emory University, and the Birmingham/Atlanta Veterans Affairs Geriatric Research Education Clinical Center — both in Atlanta.

Address reprint requests to Dr. Ouslander at the Wesley Woods Center of Emory University, 1841 Clifton Rd., NE, Atlanta, GA 30329, or at jouslan@emory.edu.

Related Letters:

Management of Overactive Bladder
Gill S. S., Mamdani M., Rochon P. A.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2213, May 20, 2004. Correspondence

This article has been cited by other articles:

• Gomelsky, A., Dmochowski, R. R. (2009). Overactive bladder in males. Therapeutic Advances in Urology 1: 209-221 [Abstract]  
• Imamura, M., Negoro, H., Kanematsu, A., Yamamoto, S., Kimura, Y., Nagane, K., Yamasaki, T., Kanatani, I., Ito, N., Tabata, Y., Ogawa, O. (2009). Basic fibroblast growth factor causes urinary bladder overactivity through gap junction generation in the smooth muscle. Am. J. Physiol. Renal Physiol. 297: F46-F54 [Abstract] [Full Text]  
• Biastre, K., Burnakis, T. (2009). Trospium Chloride Treatment of Overactive Bladder. The Annals of Pharmacotherapy 43: 283-295 [Abstract] [Full Text]  
• Cohen, B. A. (2008). Identification, causation, alleviation, and prevention of complications (ICAP): An approach to symptom and disability management in multiple sclerosis. Neurology 71: S14-S20 [Abstract] [Full Text]  
• Maruyama, S., Tsukada, H., Nishiyama, S., Kakiuchi, T., Fukumoto, D., Oku, N., Yamada, S. (2008). In Vivo Quantitative Autoradiographic Analysis of Brain Muscarinic Receptor Occupancy by Antimuscarinic Agents for Overactive Bladder Treatment. J. Pharmacol. Exp. Ther. 325: 774-781 [Abstract] [Full Text]  
• Burnstock, G. (2007). Physiology and Pathophysiology of Purinergic Neurotransmission. Physiol. Rev. 87: 659-797 [Abstract] [Full Text]  
• Treadway, A. K., Canales, A. E. (2007). New Options and Strategies for the Treatment of Urinary Incontinence. Journal of Pharmacy Practice 20: 29-48 [Abstract]  
• Burnstock, G. (2006). Pathophysiology and therapeutic potential of purinergic signaling.. Pharmacol. Rev. 58: 58-86 [Abstract] [Full Text]  
• Dmitrieva, N., Berkley, K. J. (2005). Influence of estradiol on micturition thresholds in the rat: involvement of the hypogastric nerve. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R1724-R1728 [Abstract] [Full Text]  
• Holt, J. D. S., Watson, M. J., Chang, J. P., O'Neill, S. J., Wei, K., Pendergast, W., Gengo, P. J., Chang, K.-J. (2005). DPI-221 [4-(({alpha}-S)-{alpha}-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: A Novel Nonpeptide {delta} Receptor Agonist Producing Increased Micturition Interval in Normal Rats. J. Pharmacol. Exp. Ther. 315: 601-608 [Abstract] [Full Text]  
• Ruby, C. M., Hanlon, J. T., Fillenbaum, G. G., Pieper, C. F., Branch, L. G., Bump, R. C. (2005). Medication Use and Control of Urination Among Community-Dwelling Older Adults. J Aging Health 17: 661-674 [Abstract]  
• Thorneloe, K. S., Meredith, A. L., Knorn, A. M., Aldrich, R. W., Nelson, M. T. (2005). Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. Am. J. Physiol. Renal Physiol. 289: F604-F610 [Abstract] [Full Text]  
• Verhamme, K. M. C., Dieleman, J. P., Van Wijk, M. A. M., van der Lei, J., Bosch, J. L. H. R., Stricker, B. H. C., Sturkenboom, M. C. J. M. (2005). Nonsteroidal Anti-inflammatory Drugs and Increased Risk of Acute Urinary Retention. Arch Intern Med 165: 1547-1551 [Abstract] [Full Text]  
• Gill, S. S., Mamdani, M., Rochon, P. A. (2004). Management of Overactive Bladder. NEJM 350: 2213-2213 [Full Text]  
• (2004). Overview of Overactive Bladder. JWatch Neurology 2004: 9-9 [Full Text]